1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The anti-α4β7 integrin monoclonal antibody market is experiencing significant growth as targeted immunotherapies reshape standards in gastrointestinal inflammatory disease management. These treatments are attracting attention from industry leaders seeking innovative solutions, competitive differentiation, and commercial sustainability in a complex global landscape.
Market Snapshot: Anti-α4β7 Integrin Monoclonal Antibodies in Focus
This market is marked by the rising adoption of advanced immunotherapies for Crohn’s Disease, Ulcerative Colitis, and related disorders, with next-generation anti-α4β7 integrin monoclonal antibodies driving a paradigm shift in treatment. Robust clinical pipelines, regulatory milestones, and the entry of new biopharmaceutical alliances characterize a sector in transformation. Intensifying payer scrutiny and evolving reimbursement models are influencing both clinical strategy and commercialization. Across key regions, stakeholders are leveraging collaborative networks and digital health platforms to maximize therapeutic value.
Scope & Segmentation
This comprehensive report provides a detailed analysis of anti-α4β7 integrin monoclonal antibody market dynamics, focusing on the following segments and regions:
- Indications: Crohn’s Disease (subtypes: Colonic, Ileal, Ileocolonic), Indeterminate Colitis, Microscopic Colitis, Ulcerative Colitis (Left-Sided Colitis, Pancolitis, Proctitis)
- Administration Routes: Intravenous Infusion, Subcutaneous Injection
- Line of Therapy: First Line, Second Line, Third Line and Beyond
- Distribution Channels: Hospital Pharmacy (Inpatient, Outpatient), Retail Pharmacy (Chain, Independent), Specialty Pharmacy (Hospital-Affiliated, Independent)
- Patient Age Groups: Adult, Geriatric, Pediatric
- Dosage Forms: Autoinjector, Prefilled Syringe, Single Dose Vial
- Regions: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
- Leading Companies: Takeda Pharmaceutical Company Limited, AbbVie Inc
Key Takeaways for Senior Decision-Makers
- Anti-α4β7 integrin monoclonal antibody innovations are shaping new treatment paradigms through refined molecular engineering and patient-centric stratification.
- Adoption is diversifying, reflecting tailored administration routes, dosage preferences, and demographic variation, advancing toward personalized care models.
- Payer dynamics are evolving, with outcome-based agreements and real-world data generation influencing access, pricing, and long-term revenue models.
- Regional variations in regulatory frameworks and healthcare infrastructure require localized commercial and operational strategies for successful market entry.
- Strategic alliances, intellectual property initiatives, and manufacturing investments underpin the competitive landscape and future growth potential.
Tariff Impact: Navigating U.S. Trade Policy Changes
Recent United States tariff measures, effective in 2025, are altering supply chains and sourcing strategies for anti-α4β7 integrin monoclonal antibody developers. Elevated duties on recombinant proteins and specialized excipients are prompting a reassessment of supplier relationships, distribution logistics, and procurement terms. Companies are responding by localizing production, managing inventory with greater precision, and increasing regulatory engagement to address classification and exemption status. These adjustments emphasize the value of operational agility and risk mitigation under changing trade environments.
Methodology & Data Sources
The analysis is grounded in a rigorous research framework combining primary interviews with experts—including clinicians, regulatory specialists, and commercial strategists—with exhaustive secondary reviews of peer-reviewed literature, regulatory filings, conference materials, and corporate disclosures. Triangulation of qualitative and quantitative inputs, supported by consistency checks, ensured robust and actionable insights for the anti-α4β7 integrin monoclonal antibody market.
Why This Report Matters
- Offers in-depth, segment-specific analysis, enabling senior decision-makers to identify growth drivers and address operational challenges in the anti-α4β7 integrin monoclonal antibody market.
- Provides actionable insights on regulatory, technological, and commercial factors critical for optimizing portfolio strategies and market expansion.
Conclusion
This report presents a holistic framework for navigating the evolving anti-α4β7 integrin monoclonal antibody therapeutic landscape. By synthesizing clinical, commercial, and policy insights, it supports proactive and informed strategic initiatives across global markets.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of anti-a4ß7 integrin therapies for ulcerative colitis driven by emerging real-world evidence supporting improved remission rates
5.2. Competitive landscape intensifies as biosimilar candidates targeting a4ß7 integrin antibodies advance into phase III clinical trials
5.3. Novel subcutaneous formulations of anti-a4ß7 integrin antibodies advance to late-stage development enhancing patient convenience and adherence
5.4. Strategic collaborations between biotech and pharma firms accelerate anti-a4ß7 integrin antibody commercialization in key emerging markets
5.5. Regulatory bodies review accelerated approval pathways for next-generation anti-a4ß7 integrin monoclonal antibodies based on surrogate endpoints
5.6. Expansion of indication research for anti-a4ß7 integrin antibodies into Crohn’s disease and other immune-mediated inflammatory disorders
5.7. Pricing and reimbursement negotiations intensify as payers assess the value proposition of high-cost anti-a4ß7 integrin therapies
5.8. Technological innovations in antibody engineering optimize a4ß7 integrin binding affinity while minimizing immunogenicity risks
5.2. Competitive landscape intensifies as biosimilar candidates targeting a4ß7 integrin antibodies advance into phase III clinical trials
5.3. Novel subcutaneous formulations of anti-a4ß7 integrin antibodies advance to late-stage development enhancing patient convenience and adherence
5.4. Strategic collaborations between biotech and pharma firms accelerate anti-a4ß7 integrin antibody commercialization in key emerging markets
5.5. Regulatory bodies review accelerated approval pathways for next-generation anti-a4ß7 integrin monoclonal antibodies based on surrogate endpoints
5.6. Expansion of indication research for anti-a4ß7 integrin antibodies into Crohn’s disease and other immune-mediated inflammatory disorders
5.7. Pricing and reimbursement negotiations intensify as payers assess the value proposition of high-cost anti-a4ß7 integrin therapies
5.8. Technological innovations in antibody engineering optimize a4ß7 integrin binding affinity while minimizing immunogenicity risks
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Indication
8.1. Introduction
8.2. Crohn's Disease
8.2.1. Colonic
8.2.2. Ileal
8.2.3. Ileocolonic
8.3. Indeterminate Colitis
8.4. Microscopic Colitis
8.5. Ulcerative Colitis
8.5.1. Left-Sided Colitis
8.5.2. Pancolitis
8.5.3. Proctitis
8.2. Crohn's Disease
8.2.1. Colonic
8.2.2. Ileal
8.2.3. Ileocolonic
8.3. Indeterminate Colitis
8.4. Microscopic Colitis
8.5. Ulcerative Colitis
8.5.1. Left-Sided Colitis
8.5.2. Pancolitis
8.5.3. Proctitis
9. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Administration Route
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Hospitals
11.2.2. Outpatient Hospitals
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
11.4. Specialty Pharmacy
11.4.1. Hospital Affiliated Specialty Pharmacy
11.4.2. Independent Specialty Pharmacy
11.2. Hospital Pharmacy
11.2.1. Inpatient Hospitals
11.2.2. Outpatient Hospitals
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
11.4. Specialty Pharmacy
11.4.1. Hospital Affiliated Specialty Pharmacy
11.4.2. Independent Specialty Pharmacy
12. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Dosage Form
13.1. Introduction
13.2. Autoinjector
13.3. Prefilled Syringe
13.4. Single Dose Vial
13.2. Autoinjector
13.3. Prefilled Syringe
13.4. Single Dose Vial
14. Americas Anti-a4ß7 Integrin Monoclonal Antibody Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anti-a4ß7 Integrin Monoclonal Antibody Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Takeda Pharmaceutical Company Limited
17.3.2. AbbVie Inc
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Takeda Pharmaceutical Company Limited
17.3.2. AbbVie Inc
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHAI
FIGURE 28. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 30. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHAI
FIGURE 28. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 30. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY I
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY I
Samples
LOADING...
Companies Mentioned
The companies profiled in this Anti-α4β7 Integrin Monoclonal Antibody market report include:- Takeda Pharmaceutical Company Limited
- AbbVie Inc
